These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37224929)

  • 21. Development of an Excipient-Free Peptide Dry Powder Inhalation for the Treatment of Pulmonary Fibrosis.
    Zhang Y; MacKenzie B; Koleng JJ; Maier E; Warnken ZN; Williams RO
    Mol Pharm; 2020 Feb; 17(2):632-644. PubMed ID: 31913640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
    Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
    Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
    Li X; Vogt FG; Hayes D; Mansour HM
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.
    Meenach SA; Vogt FG; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
    Int J Nanomedicine; 2013; 8():275-93. PubMed ID: 23355776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
    Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R
    Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmaceutical aerosols for the treatment and prevention of tuberculosis.
    Hanif SN; Garcia-Contreras L
    Front Cell Infect Microbiol; 2012; 2():118. PubMed ID: 22973562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
    Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
    J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
    Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
    Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.
    Meenach SA; Anderson KW; Zach Hilt J; McGarry RC; Mansour HM
    Eur J Pharm Sci; 2013 Jul; 49(4):699-711. PubMed ID: 23707466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physicochemical and Pharmacokinetic Evaluation of Spray-Dried Coformulation of
    Lu P; Xing Y; Peng H; Liu Z; Zhou QT; Xue Z; Ma Z; Kebebe D; Zhang B; Liu H
    J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):73-82. PubMed ID: 31660760
    [No Abstract]   [Full Text] [Related]  

  • 32. Preparation and Characterization of Inhalable Ivermectin Powders as a Potential COVID-19 Therapy.
    Albariqi AH; Ke WR; Khanal D; Kalfas S; Tang P; Britton WJ; Drago J; Chan HK
    J Aerosol Med Pulm Drug Deliv; 2022 Oct; 35(5):239-251. PubMed ID: 35275749
    [No Abstract]   [Full Text] [Related]  

  • 33. Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery.
    Gomez AI; Acosta MF; Muralidharan P; Yuan JX; Black SM; Hayes D; Mansour HM
    Pulm Pharmacol Ther; 2020 Oct; 64():101975. PubMed ID: 33137515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Development of an Inhalation Dry Powder Preparation Method without Heat-drying Process].
    Ito T
    Yakugaku Zasshi; 2023; 143(4):353-358. PubMed ID: 37005236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optical photothermal infrared spectroscopy for nanochemical analysis of pharmaceutical dry powder aerosols.
    Khanal D; Kim J; Zhang J; Ke WR; Holl MMB; Chan HK
    Int J Pharm; 2023 Feb; 632():122563. PubMed ID: 36586629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs.
    Kukut Hatipoglu M; Hickey AJ; Garcia-Contreras L
    Int J Pharm; 2018 Oct; 549(1-2):306-316. PubMed ID: 30077761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
    Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
    Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance.
    Stegemann S; Faulhammer E; Pinto JT; Paudel A
    Int J Pharm; 2022 Feb; 614():121445. PubMed ID: 34998921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration.
    Seow HC; Liao Q; Lau ATY; Leung SWS; Yuan S; Lam JKW
    Int J Pharm; 2022 May; 619():121704. PubMed ID: 35358643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.